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Aims: The aim of this study was to investigate whether and how metformin ameliorated endothelial
dysfunction induced by ﬂuctuating glucose (FG) in human umbilical vein endothelial cells (HUVECs).
Methods: HUVECs, which were exposed to FG to induce endothelial dysfunction, were incubated with nitric oxide
synthase (NOS) inhibitor N-nitro-L-arginine-methyl ester (L-NAME), nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase inhibitor apocynin, metformin and/or adenosine monophosphate-activated protein kinase
(AMPK) inhibitor compound C. The oxidative stress and endothelial NOS (eNOS) coupling were evaluated.
Results: FG induced endothelial dysfunction as indicated by increased reactive oxygen species (ROS) generation and
decreased nitric oxide (NO) production. Although FG increased eNOS phosphorylation, uncoupled eNOS was
evidenced by downregulated guanosine 5′-triphosphate cyclohydrolase 1 (GTPCH1) and tetrahydrobiopterin (BH4)
levels. FG also upregulated the level of p47-phox, a subunit of NADPH oxidase. Similar to L-NAME and apocynin,
metformin ameliorated the FG-induced endothelial dysfunction by decreasing ROS generation. Furthermore,
metformin recoupled eNOS through upregulating GTPCH1 and BH4 levels, and attenuated the upregulation of
p47-phox in FG-treated HUVECs. Addition of compound C abolished the above effects of metformin.
Conclusion: Metformin improves the FG-induced endothelial dysfunction in HUVECs. The protective effect of
metformin may be mediated through activation of GTPCH1-mediated eNOS recoupling and inhibition of NADPH
oxidase via an AMPK-dependent pathway.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Macrovascular disease is a major chronic complication of diabetes
mellitus. Endothelial dysfunction, characterized by reduced nitric oxide
(NO) bioavailability, is involved in the initiation and progression of
diabetic vascular complications (Davignon & Ganz, 2004; Esper et al.,
2006). The endothelial nitric oxide synthase (eNOS) is responsible for
most of the vascular NO production. eNOS oxidizes substrate L-argininetherwise, are declared by the
crinology, Beijing Chaoyang
Road, Beijing, 100020, China.
ology and Metabolism, Peking
dian District, Beijing, 100191,
ho66@bjmu.edu.cn (T. Hong).
Inc. This is an open access article uto L-citrulline and NO (Forstermann & Munzel, 2006). When the
expression and activity of eNOS decreases or eNOS becomes uncoupled,
reactive oxygen species (ROS) will generate instead of NO, and
ultimately lead to endothelial dysfunction (Takimoto et al., 2005).
Tetrahydrobiopterin (BH4) is an essential cofactor to sustain the dimer
structure and bioactivity of eNOS. BH4 deﬁciency could induce eNOS
uncoupling. Guanosine 5′-triphosphate cyclohydrolase 1 (GTPCH1) is a
key rate-limiting enzyme of BH4 synthesis, and plays an important role
in maintaining BH4 level and NO production. Inhibition of GTPCH1
results in downregulation of BH4 level and eNOS uncoupling, and thus
leads to endothelial dysfunction (Wang et al., 2008).
Postprandial hyperglycemia, as well as hypoglycemic events, is an
independent risk factor for cardiovascular complications in diabetic
patients (Suh & Kim, 2015). Studies have shown that ﬂuctuating
glucose (FG) exhibits a more speciﬁc triggering effect on oxidative
stress than chronic sustained hyperglycemia in patients with type 2
diabetes (Monnier et al., 2006). Likewise, compared with chronic high
glucose, FG can more easily induce apoptosis, upregulation ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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umbilical vein endothelial cells (HUVECs) and in patients with type 2
diabetes (Monnier et al., 2006; Quagliaro et al., 2005; Risso, Mercuri,
Quagliaro, Damante, & Ceriello, 2001). However, the underlying
mechanisms are still elusive. Whether FG could decrease GTPCH1
expression and BH4 level and accordingly induce eNOS uncoupling is
not well described.
Metformin, one of the most widely used anti-diabetic agents, can
elicit protective potency in the cardiovascular system independent of
glucose-lowering effects (Anfossi, Russo, Bonomo, & Trovati, 2010).
Adenosine monophosphate-activated protein kinase (AMPK) signal-
ing pathway plays a pivotal role in the effects of metformin. Notably, a
recent study reported that metformin could promote eNOS phos-
phorylation and increase NO production by activating AMPK, and
consequently improve the progression of heart failure in dogs (Sasaki
et al., 2009). However, whether metformin could regulate eNOS
phosphorylation in vascular endothelial cells, especially in human
cells, is not fully known.
In this study, we aimed to investigate the inﬂuence of FG on
GTPCH1-mediated eNOS coupling in cultured HUVECs, and to
investigate whether and how metformin ameliorate oxidative stress
in the endothelial cells.
2. Materials and methods
2.1. Reagents
Metformin, D-glucose, mannitol, β-endothelial cell growth factor,
compound C (CC), N-nitro-L-arginine-methyl ester (L-NAME), apocynin,
and ROS detection kit were purchased from Sigma (St. Louis, MO).
Medium 199 and fetal bovine serumwere fromHyclone (Logan, UT), and
other reagents for cell culture were from Invitrogen (Carlsbad, CA).
Anti-eNOS monoclonal antibody and anti-phospho-Ser-1177 eNOS
antibody were from BD Biosciences (San Jose, CA); anti-AMPK and
anti-phospho-Thr-172 AMPK antibodies were from Cell Signaling
Technology (Beverly, MA); anti-GTPCH1 antibody was from Abnova
(Taibei, China); and anti-p47-phox and anti-β-actin antibodieswere from
Santa Cruz Biotechnology (Santa Cruz, CA). IRDye 800CW-conjugated
goat anti-rabbit and goat anti-mouse IgGs were purchased from LI-COR
Biosciences (Lincoln, NE). Other reagents for Western blot were from
Bio-Rad Laboratories (Hercules, CA).
2.2. Cell culture
Human umbilical cord samples were collected from healthy
donors. Written informed consent was obtained from pregnant
women before labor. HUVECs were isolated by collagenase digestion
as previously described (Liu et al., 2011) and cultured in the
endothelial cell growth medium (M199, 10% fetal bovine serum,
4.16 ng/mL β-endothelial cell growth factor, 8.2 mg/mL heparin, and
1× GlutaMax). The HUVECs of 5 to 6 passage were used in all
experiments, which were examined to ensure speciﬁc characteristics
of endothelial cells by cytochemical staining. The in vitro model of
endothelial dysfunctionwas established by exposure of HUVECs to FG.
The cell treatment conditions were divided into four groups: normal
glucose control (NC, 5.6 mmol/L glucose), constant high glucose (HG,
30 mmol/L glucose), FG (5.6 and 30 mmol/L glucose, alternated every
8 h), and hyperosmotic control (HC, 5.6 mmol/L glucose + 24.4 mmol/L
mannitol). To detect the effects of metformin, HUVECs were treated
with 2 mmol/L metformin in most of the conditions. To clarify the
involved signaling pathways, the nitric oxide synthase (NOS) inhibitor
L-NAME (300 μmol/L), nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase inhibitor apocynin (100 μmol/L), or AMPK inhibitor
CC (10 μmol/L) was added. The cells in all these groups were incubated
for 72 h. All experiments were performed four times with each group
in triplicate.2.3. Measurement of NO
NO level in cell supernatant was measured by ELISA kits according
to the manufacturer's protocols (Jiamay Biotech, Beijing, China). The
NO level in the NC group was set up as 100%.
2.4. Measurement of intracellular ROS
Determination of intracellular oxidant production in the HUVECs was
based on oxidation of a ROS probe dye 2′7′-dichilroﬂurescin diacetate
(20 μmol/L) by intracellular ROS, resulting in formation of the ﬂuorescent
compound 2′7′- dichilroﬂurescin (DCF). The DCF ﬂuorescence was
monitored with a ﬂow cytometer (BD Biosciences) or a laser confocal
microscope (LSM 510 META, Carl Zeiss, Jena, Germany). The intracellular
ROS level in the NC group was set up as 100%.
2.5. Measurement of intracellular BH4
High performance liquid chromatography (HPLC) was used for the
measurement of intracellular BH4. Brieﬂy, cells were lysed in distilled
water containing 1 mmol/L dithiothreitol, 50 mmol/L Tris-HCl and
1 mmol/L EDTA. The cell lysate (90 μL) was treated with acid solution
(10 μL, 1.5 mmol/L HClO4 : 2 mmol/L H3PO4 = 1:1), and centrifuged
at 13,000 g for 10 min. The supernatant (90 μL) was treated with acid
iodine solution (10 μL, 1% iodine and 2% KI in 1 mmol/L HCl solution)
and incubated for 60 min in the dark, and then fresh ascorbic acid
(5 μL, 20 mg/mL in water) was added to reduce excess iodine. After
centrifugation, the supernatant (90 μL) was detected. The above
process is called acid oxidation, which is to determine the total
biopterin [BH4, dihydropterin (BH2), and oxidized biopterin]. The
below process is called alkaline oxidation, which is to determine the
levels of BH2 and biopterin. The cell lysate (80 μL) was treated with
NaOH (10 μL, 1 mmol/L) and alkaline iodine solution (10 μL, 1% iodine
and 2% KI in 1 mmol/L NaOH), and incubated for 60 min in the dark.
Then, 20 μL H3PO4 (1 mmol/L) and 5 μL fresh ascorbic acid were
added. After centrifugation, the supernatant (120 μL) was detected by
an HPLC system with an auto sampler and a ﬂuorescence detector
(Agilent 1100, Agilent Technologies, Santa Clara, CA). A Hypersil C18
column (4.6 mm × 250 mm, 5 μm) was used for separation of
biopterin with a mobile phase of ration of methanol to water (5:95,
v/v) running at a ﬂow rate of 1.0 mL/min. The retention time of
biopterin was approximately 14 min, and the excitation and emission
wavelengths were 350 and 440 nm, respectively. Compounds were
quantitated by their peak height in comparison with external
standards. BH4 concentrations, expressed as pmol/mg protein, were
calculated by subtracting BH2 + biopterin from total biopterin.
2.6. Western blot analysis
HUVECs were lysed with RIPA cell-lysis buffer (Thermo Fisher
Scientiﬁc, Waltham, MA) containing protease inhibitor cocktail
(Roche, Basel, Switzerland). The protein content was assayed by a
BCA protein assay reagent (Thermo Fisher Scientiﬁc, Waltham, MA).
Proteins were loaded to SDS-PAGE and transferred to nitrocellulose
membranes. After incubation in blocking buffer (5% BSA in TBS-T), the
membranes were incubated with primary antibody (all at 1:1,000
dilutions) overnight at 4 °C, followed by incubation with IRDye
800CW-conjugated goat anti-rabbit or anti-mouse IgG. Protein bands
were visualized by Odyssey infrared imaging system (LI-COR
Biosciences), and the intensity of each band was measured by the
accompanying software.
2.7. Statistical analysis
Data were presented as means ± SD. The differences between
groups were analyzed by one-way ANOVA. Thereafter, LSD (least
1019H. An et al. / Journal of Diabetes and Its Complications 30 (2016) 1017–1024signiﬁcant difference) was used to analyze the differences between
two groups. P b 0.05 was considered statistically signiﬁcant. All
analyses were performed using SPSS 16.0 J for Windows (SPSS
Japan Inc., Tokyo, Japan).
3. Results
3.1. Effects of FG on ROS generation and NO production in HUVECs
Under a confocal microscope, the signal intensity of intracellular ROS
was obviously increased in the HUVECs of HG and FG groups relative to
the NC group (Fig. 1A). Compared with the NC group, the level of
intracellularROSwassigniﬁcantly increased in thecellsofHG(P = 0.007)
and FG groups (P b 0.001) as detected by a ﬂow cytometer. Notably, the
ROS level was even higher in the cells of FG group (P = 0.01) than that in
theHGgroup (Fig. 1B, SupplementaryTable1). Conversely, the level ofNO
was signiﬁcantly reduced in the cells of HG (P = 0.001) and FG
(P b 0.001) groups compared to the NC group. Similarly, an even lower
level of NO was found in the cells exposed to FG (P = 0.008) than that
resulted from HG exposure (Fig. 1C, Supplementary Table 1). However,
there was no signiﬁcant difference in the levels of ROS (P = 0.899) and
NO (P = 0.520) between the NC and HC groups (Fig. 1B and C,
Supplementary Table 1). These results suggested that FG induced
endothelial dysfunction characterized by increased ROS generation and
decreased NO production.
3.2. Effects of FG on eNOS coupling and NADPH oxidase level in HUVECs
Unexpectedly, the level of phosphorylated eNOS (p-eNOS) was
remarkably increased in the HUVECs of HG and FG groups (both
P b 0.001) compared to the NC group (Fig. 2A, Supplementary Table
2). BH4 is an essential cofactor to sustain the bioactivity of eNOS.
Therefore, we measured the level of BH4 in the HUVECs by HPLC.
Compared with the NC group, the BH4 level was signiﬁcantly reduced
in the cells of HG (P b 0.001) and FG (P = 0.001) groups (Fig. 2B,
Supplementary Table 2). In line with this result, the level of GTPCH1, a
key rate-limiting enzyme of BH4 synthesis, was markedly decreased
in the cells of HG and FG groups (both P b 0.001) compared to the NCFig. 1. Effects of FG on ROS generation and NO production in HUVECs. A: Representative
Representative photographs (left panel) and quantiﬁcation (right panel) of ROS level detec
expressed as means ± SD. All experiments were performed four times with each group in tr
constant high glucose; FG, ﬂuctuating glucose; HC, hyperosmotic control.group. Notably, the level of GTPCH1 was even lower in the cells of FG
group (P = 0.018) than that in the HG group (Fig. 2C, Supplementary
Table 2). Nevertheless, there was no signiﬁcant difference in the levels
of p-eNOS (P = 0.757), BH4 (P = 0.697) and GTPCH1 (P = 0.614)
between the NC and HC groups (Fig. 2A–C, Supplementary Table 2).
These results suggested that FG induced eNOS uncoupling by
downregulating the levels of both GTPCH1 and BH4.
NADPH oxidases may also induce ROS generation in the vascula-
ture and result in endothelial dysfunction. Our result showed that the
level of p47-phox, a subunit of NADPH oxidase, was signiﬁcantly
augmented in the HUVECs of HG and FG groups (both P b 0.001)
compared with the NC group (Fig. 2D, Supplementary Table 2).
Importantly, addition of either L-NAME (an inhibitor of NOS) or
apocynin (an inhibitor of NADPH oxidases) signiﬁcantly attenuated
the FG-induced increase of ROS generation (both P b 0.001) in the
HUVECs (Fig. 2E, Supplementary Table 2). These results indicated that
the increased ROS generation in the FG-treated cells was at least
partly due to either eNOS uncoupling or upregulated NADPH oxidase.3.3. Effects of metformin on ROS generation and NO production in the
FG-treated HUVECs
Comparedwith theNC group, FG exposure signiﬁcantly decreased the
level of phosphorylated AMPK (p-AMPK) in the HUVECs (P b 0.001). As
expected, metformin (0.2–10 mmol/L) dose-dependently increased the
level of p-AMPK (P b 0.05) in the FG-treated cells (Fig. 3A, Supplementary
Table 3). The metformin-induced (2 mmol/L) upregulation of p-AMPK
levelwasblockedby10 μmol/LCC, anAMPK inhibitor (P b 0.001) in these
cells (Fig. 3B, Supplementary Table 3). Notably, metformin (2 mmol/L)
inhibited the FG-induced augmentation of ROS generation (P b 0.001).
This effect of metformin was reversed by adding CC (P = 0.013) in the
FG-impaired cells (Fig. 3C, Supplementary Table 3).Moreover, metformin
(2 mmol/L) attenuated the FG-induceddownregulation ofNOproduction
(P b 0.001), which was also diminished by addition of CC (P = 0.022) in
the FG-treated cells (Fig. 3D, Supplementary Table 3). These results
suggested that metformin might attenuate the FG-induced endothelial
dysfunction via activation of AMPK signaling pathway.photographs of intracellular ROS signals detected by a laser confocal microscope. B:
ted by a ﬂow cytometer. C: Quantiﬁcation of NO level measured by ELISA. Values are
iplicate. *P b 0.05, vs NC group; §P b 0.05, vs HG group. NC, normal glucose control; HG,
Fig. 2. Effects of FG on eNOS coupling and NADPH oxidase level in HUVECs. A: Representative photographs and quantiﬁcation of phosphorylated eNOS (p-eNOS) level measured by
Western blot. B: Quantiﬁcation of BH4 level detected by HPLC. C and D: Representative photographs and quantiﬁcation of GTPCH1 (C) and p47-phox (D) levels measured byWestern
blot. E: Representative photographs (left panel) and quantiﬁcation (right panel) of ROS level detected by a ﬂow cytometer. Values are expressed as means ± SD. All experiments
were performed four times with each group in triplicate. *P b 0.05, vs NC group; §P b 0.05, vs HG group; †P b 0.05, vs FG group. NC, normal glucose control; HG, constant high
glucose; FG, ﬂuctuating glucose; HC, hyperosmotic control; L-NAME, N-nitro-L-arginine-methyl ester, an NOS inhibitor; Apo, apocynin, an inhibitor of NADPH oxidases.
Fig. 3. Effects of metformin on AMPK phosphorylation and the levels of ROS and NO in HUVECs exposed to FG. A and B: Representative photographs and quantiﬁcation of
phosphorylated AMPK (p-AMPK) level measured byWestern blot. C: Quantiﬁcation of ROS generation detected by a ﬂow cytometer. D: Quantiﬁcation of NO productionmeasured by
ELISA. Values are expressed as means ± SD. All experiments were performed four times with each group in triplicate. *P b 0.05, vs NC group; †P b 0.05, vs FG group; &P b 0.05, vs
FG + M group. NC, normal glucose control; FG, ﬂuctuating glucose; M, metformin; CC, compound C.
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the FG-treated HUVECs
As shown in Fig. 4A and Supplementary Table 4 (also see Fig. 2A), the
level of p-eNOS in the HUVECs was signiﬁcantly upregulated by FG
(P b 0.001). Interestingly, metformin (2 mmol/L) could further increase
the level of p-eNOS in the FG-treated cells (P b 0.001). The AMPK inhibitor
CC (10 μmol/L) remarkably enhanced the metformin-induced upregula-
tionof p-eNOS level (P b 0.001), instead of inhibiting it, in the FG-impaired
cells. We next investigated the effects of metformin on the levels of BH4
and GTPCH1. As shown in Fig. 4B and C and Supplementary Table 4,
metformin signiﬁcantly attenuated the FG-induced reduction of BH4 and
GTPCH1 levels (both P b 0.001) in theHUVECs. Importantly, additionof CC
abolished the above effects ofmetformin on BH4 andGTPCH1 levels (both
P b 0.001) in the FG-treated cells. These results indicated that metformin
promotedeNOSrecoupling throughactivationofAMPKsignalingpathway.
As shown in Fig. 4D and Supplementary Table 4, metformin also
signiﬁcantly inhibited the FG-induced upregulation of p47-phox level
in the HUVECs (P b 0.001). Likewise, this effect of metformin in the
FG-treated cells was blocked by adding CC (P b 0.001), suggesting
that metformin downregulated the level of this NADPH oxidase
subunit via activation of AMPK signaling pathway.
4. Discussion
Our studies showed that FG, similar or even signiﬁcant to HG,
induced oxidative stress as indicated by increased ROS generation andFig. 4. Effects of metformin on eNOS coupling and NADPH oxidase level in HUVECs exposed
Western blot. B: Quantiﬁcation of BH4 level detected by HPLC. C and D: Representative photo
blot. Values are expressed as means ± SD. All experiments were performed four times wit
FG + M group. NC, normal glucose control; FG, ﬂuctuating glucose; M, metformin; CC: comdecreased NO production in the HUVECs. The endothelial dysfunction
might be mediated via upregulation of the NADPH oxidase subunit
p47-phox, as well as induction of eNOS uncoupling through
downregulation of GTPCH1 and BH4 levels. Metformin upregulated
GTPCH1 and BH4 levels, promoted eNOS recoupling, and subsequent-
ly inhibited ROS generation and increased NO production via AMPK
signaling pathway. Furthermore, metformin might also function as a
protective factor of the endothelial cells against oxidative stress by
downregulating the NADPH oxidase.
Macroangiopathy is one of the main chronic complications in type
2 diabetes, which signiﬁcantly increases mortality risk. Hyperglyce-
mia, which induces vascular endothelium damage by oxidative stress,
non-enzymatic glycosylation and other mechanisms, is an important
initial factor of diabetic angiopathy and atherosclerosis (Brownlee,
2001). In recent years, a series of studies have shown that diabetic
vascular complications not only are associated with mean blood
glucose level, but also have a close relationship with glucose
variability (Monnier & Colette, 2008). Endothelial cell damage caused
by FG may be more severe than that resulted from HG (Monnier et al.,
2006; Quagliaro et al., 2005; Risso et al., 2001). In line with those
observations, our study showed that higher ROS generation and lower
NO production were found in the HUVECs of FG group than that in HG
group, suggesting that FG could induce more severe endothelial
dysfunction than HG.
Endothelial dysfunction, a common pathophysiological basis of
diabetic angiopathy, is characterized by decreased NO bioavailability
(Davignon & Ganz, 2004; Esper et al., 2006). NO is derived fromto FG. A: Representative photographs and quantiﬁcation of p-eNOS level measured by
graphs and quantiﬁcation of GTPCH1 (C) and p47-phox (D) levels measured byWestern
h each group in triplicate. *P b 0.05, vs NC group; †P b 0.05, vs FG group; &P b 0.05, vs
pound C.
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conditions, as an important regulator in vascular homeostasis, NO can
regulate vascular tone and blood pressure, and inhibit platelet
aggregation and adhesion (Napoli et al., 2006). However, under the
pathophysiological conditions such as diabetes, the bioavailability of
NO is signiﬁcantly decreased. The declined NO bioavailability is
mainly due to decreased production of NO and increased inactivation
of NO, the latter of which ismainly caused by the ultra oxygen anion. A
number of studies have demonstrated that decreased NO production
is not entirely caused by decreased eNOS expression. Surprisingly,
overexpression of eNOS accelerates atherosclerosis in ApoE-deﬁcient
mice (Ozaki et al., 2002). A likely explanation is that eNOS
overexpression in the ApoE-deﬁcient mice leads to eNOS uncoupling.
Evidence for eNOS uncoupling has been also apparent in patients with
endothelial dysfunction resulting from diabetes or hypercholesterol-
emia (Li, Horke, & Forstermann, 2014). When eNOS uncoupled,
superoxide is generated at the expense of NO production. The
uncoupled eNOS becomes the new sources of ROS and mediates the
damage on vascular endothelium (Li & Forstermann, 2013). Our
results showed that both HG and FG upregulated eNOS phosphory-
lation. Since this alteration was in parallel to the upregulation of ROS
generation and downregulation of NO production, we concluded that
the FG-induced upregulation of phosphorylated eNOS might be
uncoupled. Under this condition, eNOS was converted from an
NO-producing enzyme to a molecule that generated superoxide. It is
worth noting that eNOS uncoupling is not an “all or none”
phenomenon. Uncoupled and coupled eNOS can exist at the same
time (Ponnuswamy et al., 2012).
The eNOS uncoupling can be induced by many risk factors, such as
diabetes and hypertension. Several mechanisms for eNOS uncoupling are
implicated, such as deﬁciency and/or oxidative degradation of the eNOS
cofactor BH4, depletion of the substrate L-arginine, and accumulation of
the endogenous eNOS inhibitor asymmetrical dimethylarginine, among
which BH4 deﬁciency is the pivotal factor (Li & Forstermann, 2013). In the
present study, both FG andHG reduced BH4 level in theHUVECs. Addition
of the NOS inhibitor L-NAME partially attenuated the FG-induced
augmentation of ROS generation in the HUVECs. These results indicate
that FG may cause endothelial dysfunction by inducing eNOS uncoupling
due to decreased BH4 level.
GTPCH1 is a key rate-limiting enzyme for de novo synthesis of
BH4, and thereby affects eNOS coupling state. In cultured aortic
endothelial cells, inhibition of GTPCH1 by either drugs or RNA
interference results in eNOS uncoupling and endothelial dysfunction
(Wang et al., 2008). Thus, the inhibited expression and activity of
GTPCH1 may be one of the mechanisms leading to endothelial
dysfunction in diabetics. In this study, signiﬁcant decrease of GTPCH1
level in parallel to reduction of BH4 level was found in the HUVECs of
HG and FG groups, which led to eNOS uncoupling, and thus resulted in
endothelial dysfunction.
NADPH oxidases, the multi-subunit enzyme complexes, are major
sources of ROS in the vasculature. p47-phox, a regulatory subunit of
NADPH oxidase, is required for activation of Nox catalytic subunit in
vascular cells (Li et al., 2014). A recent study reported that HG induced
p47-phox translocation and phosphorylation in cultured human
aortic endothelial cells (Batchuluun et al., 2014). In this study, we
found that FG markedly upregulated p47-phox level and thus
augmented NADPH oxidase activity, which might also contribute to
the increased ROS generation in the FG-treated HUVECs. Intriguingly,
when oxidative stress was enhanced, superoxide modestly and
peroxynitrite strongly oxidize BH4 to BH2, leading to BH4 deﬁciency
(Li & Forstermann, 2013). Therefore, the enhanced BH4 oxidation due
to oxidative stress, together with the reduced de novo BH4 synthesis
due to downregulation of GTPCH1, signiﬁcantly decreased BH4 level
and thus led to eNOS uncoupling. The uncoupled eNOS generated
more superoxide and accelerated oxidative stress. As a result, a vicious
circle sets up (Laursen et al., 2001). Since oxidative stress is involvedin endothelial dysfunction and atherosclerosis (Li et al., 2014), it is
conceivable that antioxidants including carotenoids may be beneﬁcial
to cardiovascular system (Ciccone et al., 2013).
Metformin, a biguanide, is themost widely used anti-diabetic agent.
A series of animal and clinical studies have demonstrated its beneﬁcial
and protective effects on cardiovascular system. The United Kingdom
prospective diabetes study (UKPDS) showed that metformin could
reduce risk of cardiovasculardeath andmyocardial infarction in obeseor
overweight patients with type 2 diabetes (UKPDS-Group, 1998). The
10 years follow-up study after UKPDS further indicated that the
beneﬁcial effects of metformin in the intensive treatment group could
be sustained (Holman, Paul, Bethel, Matthews, & Neil, 2008). Other
studies reported that metformin signiﬁcantly improved vascular
endothelial function as assessed byﬂow-mediateddilation, and resulted
in the regression of carotid intima-media thickness in patientswith type
2 diabetes and those with metabolic syndrome (Meaney et al., 2008).
One explanation of these beneﬁts may be that metformin has direct
vascular endothelial protective effects independent of its
glucose-lowering effect (Anfossi et al., 2010). A previous report showed
that oral administration of metformin in diabetic mice improved the
damaged endothelium-dependent vasodilation function by suppressing
26S proteasome-mediated GTPCH1 degradation (Wang, Xu, Song,
Viollet, & Zou, 2009). One recent study demonstrated that metformin
inhibited p47-phox translocation and NADPH oxidase activation, and
prevented the HG-induced oxidative stress in cultured human aortic
endothelial cells (Batchuluun et al., 2014). Another study reported that
metformin increased eNOS phosphorylation at serine 1179 (Ser1179),
increased its combination with heat shock protein 90 by activating
AMPK signaling pathway, and thereby activated eNOS, which increased
NO production and thus improved endothelial function (Davis, Xie,
Viollet, & Zou, 2006). Likewise, our results showed that metformin
reversed the FG-induced reduction of GTPCH1 and BH4 levels,
upregulation of p47-phox level, increase of ROS generation, and
reduction of NO production in the HUVECs. Taken together, metformin
does have a direct protective effect on the endothelial cells.
AMPK, a heterotrimetric protein composed of α, β and γ subunits,
has been implicated in regulating both energy metabolism and
vascular homeostasis. Activation of AMPK requires AMPK phosphor-
ylation at Thr 172, and the activated AMPK exerts various beneﬁcial
effects on glucose homeostasis and vascular system (Eriksson &
Nystrom, 2014; Ewart & Kennedy, 2011). AMPK suppresses 26S
proteasome-mediated GTPCH1 degradation and thus increases
GTPCH1 level (Wang et al., 2009). Moreover, AMPK is a physiological
suppressor of NADPH oxidase in multiple cardiovascular cell systems
(Song & Zou, 2012). In the present study, the protective effects of
metformin on the FG-impaired endothelial cells were diminished by
addition of the AMPK inhibitor CC, indicating that metformin
functions via activation of AMPK signaling pathway. However, the
precise mechanism of this process needs to be further investigated.
In conclusion, FG induces eNOS uncoupling, enhances oxidative
stress and causes endothelial cell injury in the HUVECs. Metformin
may attenuate the FG-induced oxidative endothelial cell damage
through upregulating GTPCH1 and BH4 levels, and thereby promoting
eNOS recoupling. Moreover, metformin downregulates the level of an
NADPH oxidase subunit p47-phox, thus decreasing ROS generation
and BH4 oxidation. These protective effects of metformin are at least
partially mediated via activation of AMPK signaling pathway. The
discoveries in this paper are summarized in Fig. 5.Acknowledgments
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Fig. 5. Proposed scheme of the ﬁndings in this paper. A: FG induces oxidative stress in cultured HUVECs. FG decreases the levels of GTPCH1 and BH4, thus inducing eNOS uncoupling.
The uncoupled eNOS produces ROS at the expense of NO. Moreover, FG increases the level of a NADPH oxidase subunit p47-phox and accordingly produces more ROS. These
processes potentiate oxidative stress in the cells. On the other hand, the oxidative stress decreases BH4 level by oxidizing BH4 to BH2, which further aggravates eNOS uncoupling and
oxidative stress. The vicious cycle ﬁnally leads to endothelial cell injury. B: Metformin attenuates the FG-induced oxidative stress in the HUVECs. Metformin ameliorates the
FG-induced endothelial cell damage probably through upregulating GTPCH1 and BH4 levels, and thereby promoting eNOS recoupling. The recoupled eNOS produces less ROS and
more NO. Metformin also decreases ROS generation derived from the NADPH oxidase. The diminished oxidative stress leads to less oxidation of BH4 to BH2; instead, BH2 is reduced
to BH4 by dihydrofolate reductase (DHFR). The vicious cycle of oxidative stress is blocked by metformin. Notably, the protective effects of metformin on the endothelial cells are at
least partially mediated via AMPK-dependent pathway.
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